Takehisa Kawata
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Evocalcet improved the PTH-calcium setpoint and suppressed parathyroid proliferation in mice model of primary hyperparathyroidism.
Journal: Journal of bone and mineral metabolism
Published: October 12, 2025
Evocalcet Rescues Secondary Hyperparathyroidism-driven Cortical Porosity in CKD Male Rats.
Journal: Endocrinology
Published: October 18, 2022
Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism.
Journal: PloS one
Published: March 05, 2021
Development of evocalcet for unmet needs among calcimimetic agents.
Journal: Expert review of endocrinology & metabolism
Published: June 20, 2020
The effect of evocalcet on vagus nerve activity of the gastrointestinal tract in miniature pigs.
Journal: PloS one
Published: June 02, 2020
Efficacy and Safety of Evocalcet Evaluated by Dialysate Calcium Concentration in Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis.
Journal: International journal of nephrology and renovascular disease
Published: December 21, 2019
Pharmacological and clinical profiles of a novel calcimimetic, evocalcet (ORKEDIA®)
Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica
Published: July 17, 2019
Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism.
Journal: Bioorganic & medicinal chemistry letters
Published: March 26, 2018
Showing 1-10 of 10
Last Updated: 09/26/2026